Literature DB >> 2157895

Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity.

P X Guo1, S Goebel, M E Perkus, J Taylor, E Norton, G Allen, B Languet, P Desmettre, E Paoletti.   

Abstract

The equine herpesvirus 1 glycoprotein 14 (EHV-1 gp14) gene was cloned, sequenced, and expressed by vaccinia virus recombinants. Recombinant virus vP613 elicited the production of EHV-1-neutralizing antibodies in guinea pigs and was effective in protecting hamsters from subsequent lethal EHV-1 challenge. Coexpression of EHV-1 gp14 in vaccinia virus recombinant vP634 along with EHV-1 gp13 (P. Guo, S. Goebel, S. Davis, M. E. Perkus, B. Languet, P. Desmettre, G. Allen, and E. Paoletti, J. Virol. 63:4189-4198, 1989) greatly enhanced the protective efficacy in the hamster challenge model over that obtained with single recombinants. The inoculum doses (log10) required for protection of 50% of hamsters were 6.1 (EHV-1 gp13), 5.2 (EHV-1 gp14), and less than 3.6 (vaccinia virus recombinant expressing both EHV-1 glycoproteins [gp13 and gp14]).

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2157895      PMCID： PMC249404          DOI： 10.1128/JVI.64.5.2399-2406.1990

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  55 in total

1.  Identification of a herpes simplex virus 1 glycoprotein gene within a gene cluster dispensable for growth in cell culture.

Authors:  R Longnecker; S Chatterjee; R J Whitley; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart.

Authors:  M A Swain; R W Peet; D A Galloway
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

Review 3.  Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.

Authors:  G P Allen; J T Bryans
Journal:  Prog Vet Microbiol Immunol       Date:  1986

4.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

5.  Nucleotide sequence specifying the glycoprotein gene, gB, of herpes simplex virus type 1.

Authors:  D J Bzik; B A Fox; N A DeLuca; S Person
Journal:  Virology       Date:  1984-03       Impact factor: 3.616

6.  Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.

Authors:  K L Rosenthal; J R Smiley; S South; D C Johnson
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Use of lambda gt11 and monoclonal antibodies to map the genes for the six major glycoproteins of equine herpesvirus 1.

Authors:  G P Allen; M R Yeargan
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

8.  Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.

Authors:  K J Cremer; M Mackett; C Wohlenberg; A L Notkins; B Moss
Journal:  Science       Date:  1985-05-10       Impact factor: 47.728

9.  DNA sequence analysis with a modified bacteriophage T7 DNA polymerase.

Authors:  S Tabor; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

10.  One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription.

Authors:  C Bertholet; R Drillien; R Wittek
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205
View more
  15 in total

1.  Immunization with Attenuated Equine Herpesvirus 1 Strain KyA Induces Innate Immune Responses That Protect Mice from Lethal Challenge.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

2.  Characterization of an antigenic site on glycoprotein 13 (gC) of equid herpesvirus type-1.

Authors:  R Sinclair; B J Moult; J A Mumford
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors:  D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

4.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.

Authors:  P M Smith; Y Zhang; S R Jennings; D J O'Callaghan
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  Detection of antibodies against equine herpesvirus types 1 and 4 by using recombinant protein derived from an immunodominant region of glycoprotein B.

Authors:  R Sinclair; M M Binns; E D Chirnside; J A Mumford
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

7.  Sequential interactions of structural proteins in phage phi 29 procapsid assembly.

Authors:  C S Lee; P Guo
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants.

Authors:  M Riviere; J Tartaglia; M E Perkus; E K Norton; C M Bongermino; F Lacoste; C Duret; P Desmettre; E Paoletti
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  Expression of the Marek's disease virus (MDV) homolog of glycoprotein B of herpes simplex virus by a recombinant baculovirus and its identification as the B antigen (gp100, gp60, gp49) of MDV.

Authors:  M Niikura; Y Matsuura; D Endoh; M Onuma; T Mikami
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus.

Authors:  K Nazerian; L F Lee; N Yanagida; R Ogawa
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.